Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension

Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension

May 22, 2018 PULSAR trial expands Acceleron’s pipeline into pulmonary disease CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of

Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 1, 2018–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.S. Food and Drug Administration(FDA) has granted Fast Track designation to ACE-083,

Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting

– Oral presentation to highlight preliminary results of ACE-083’s Phase 2 trial in patients with facioscapulohumeral muscular dystrophy – – Part 2 of the ongoing Phase 2 trial in patients with facioscapulohumeral muscular dystrophy has been initiated – CAMBRIDGE, Mass.–(BUSINESS